Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2021.07.19
Active substance: tetrazepam
Marketing authorizations for tetrazepam-containing drugs are being revoked because the risk-benefit ratio is unfavorable.
On 29 May 2013, the European Commission decided to suspend the marketing authorisations of medicinal products containing tetrazepam. In view of the suspension of the marketing authorisations of tetrazepam-containing medicines, the BfArM has ruled an extension of the suspension. In a notice dated 28 July 2017, the BfArM has ruled that the suspension will be extended for the time being until 31 July 2019.
In a notice dated 12.07.2019 the BfArM has again ruled an extension of the sespension of the marketing authorisations until 31.07.2021.
To the risk assessment procedure (available in German only)